185039-37-6

Basic information

• Product Name: N-[6-(2,6-Dichlorophenyl)-8-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-ylidene]acetamide
• Synonyms: N-[6-(2,6-Dichlorophenyl)-8-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-ylidene]acetamide
• CAS NO: 185039-37-6
• Molecular Formula: C₁₇H₁₄Cl₂N₄OS
• Molecular Weight: 393.29026
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 185039-37-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 558.981°C at 760 mmHg
• Flash Point: 291.861°C
• Appearance: /
• Density: 1.438g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.683
• Solubility: Chloroform, Dichloromethane, DMSO, Methanol
• CAS DataBase Reference: N-[6-(2,6-Dichlorophenyl)-8-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-ylidene]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[6-(2,6-Dichlorophenyl)-8-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-ylidene]acetamide(185039-37-6)
• EPA Substance Registry System: N-[6-(2,6-Dichlorophenyl)-8-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-ylidene]acetamide(185039-37-6)

Safety Data

• Hazardous Substances Data: 185039-37-6(Hazardous Substances Data)

Usage

Description

N-[6-(2,6-Dichlorophenyl)-8-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-ylidene]acetamide is a complex organic compound characterized by its yellow solid appearance. It is an intermediate in the synthesis of antitumor agents and tyrosine kinase inhibitors, which are crucial in the development of cancer treatments.

Uses

Used in Pharmaceutical Industry:
N-[6-(2,6-Dichlorophenyl)-8-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-ylidene]acetamide is used as an intermediate in the preparation of antitumor agents for the pharmaceutical industry. Its role is to contribute to the development of cancer treatments by being a part of the synthesis process for these life-saving drugs.
Additionally, it is used as an intermediate in the preparation of tyrosine kinase inhibitors, which are essential in the treatment of various cancers by targeting the enzymes that promote tumor growth.

InChI:InChI=1/C17H14Cl2N4OS/c1-9(24)21-16-11(14-12(18)5-4-6-13(14)19)7-10-8-20-17(25-3)22-15(10)23(16)2/h4-8H,1-3H3/b21-16-

Upstream product

• 108-24-7 acetic anhydride 
• 185039-29-6 6-(2,6-Dichlorophenyl)-8-methyl-2-methylsulfanyl-8H-pyrido[2,3-d]-pyrimidin-7-ylideneamine 
• 17759-30-7 (4-methylamino-2-methylsulfanyl-pyrimidin-5-yl)-methanol 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 76360-82-2 4-methylamino-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester 

Downstream Products

• 185039-46-7 6-(2,6-dichlorophenyl)-8-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 185039-89-8 PD-166285 
• 185039-34-3 6-(2,6-dichlorophenyl)-2-hydroxy-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 185039-62-7 6-(2,6-Dichlorophenyl)-2-methanesulfinyl-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 185039-48-9 6-(2,6-dichlorophenyl)-8-methyl-2-(methylsulfonyl)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 212391-57-6 SKI DV₂ 47 
• 185039-73-0 6-(2,6-Dichlorophenyl)-2-(4-methoxyphenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 

Relevant articles and documents

Part 3: Notch-sparing γ-secretase inhibitors: SAR studies of 2-substituted aminopyridopyrimidinones

In search for novel lead compounds as γ-secretase inhibitors, analogs of aminopyrido[2,3-d]pyrimidin-7-ones (I) were synthesized and evaluated for inhibitory effects on amyloid-β-peptide production and cleavage of the Notch1 receptor mediated by γ-secretase. Selected pyridopyrimidines, such as 1, 8, 9,10, 11 and 16 are γ-secretase inhibitors that did not have an effect on Notch1 receptor processing.

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity

While engaged in therapeutic intervention against a number of proliferative diseases, we have discovered the 2-aminopyrido[2,3- d]pyrimidin-7(8H)-ones as a novel class of potent, broadly active tyrosine kinase (TK) inhibitors. An efficient route was devel